The use of dipeptidyl peptidase-4 inhibitors to restore the insulin sensitivity and the metabolic processes in patients with MS and T2DM [333–338]; the use of IDE inhibitors to improve glucose tolerance in experimental metabolic disorders [128,129]. The gene discussed is DPP4; the disease is myeloid sarcoma.